Awareness Month Tribute
This month only, make a gift in honor of someone who has shown up for you — and they'll receive a personal thank you message from ANRF Board member and RA survivor Staci Stringer Betschart.
It's a meaningful way to celebrate the people in your village while fueling the research that's changing lives.
Make Your GiftDon't wait — this opportunity is available this month only.
Immune Boost Capital (IBC) is a strategic extension of the ANRF with the mission to provide funding to ideas that are moving from the lab to clinical development. Some investments may support ANRF grant recipients; however, the fund will actively seek opportunities from any source. IBC will select investments based on the same due diligence and criteria as traditional VC firms.
ANRF is a financial and scientific partner to IBC to support the organization in realizing our mission. However, IBC operates independently, and is run by an experienced team of investors, scientific researchers, and medical and healthcare professionals.
Substantial advancements have been achieved in diagnostic tools and effective treatments for arthritis and autoimmune diseases. However, progress has been hampered by insufficient funding for early-stage research, presenting a formidable obstacle to overall development in the field. IBC seeks to attract the additional capital needed from traditional venture capital, biotech and pharma entities to close the early-stage funding-gap and drive innovation in development of cures and treatments for those living with arthritis and related autoimmune disease.
We believe the best chance at success in bringing cures and treatments to arthritis and related autoimmune disease is to invest in early stage promising therapies, companies, and technologies, and help guide and mentor them through development. Immune Boost Capital’s targeted investment strategy is focused on guiding and advancing portfolio companies to bring them closer to clinical development. While risk is associated with early-stage investments, there is also the opportunity to advance therapies and companies in the arthritis space. As a high-impact philanthropic vehicle, all returns from the Fund’s investments will be recycled back into furthering IBC’s mission.
Immune Boost Capital serves at the vital intersection of ideas and action. By investing in new therapies and technologies, we can move emerging solutions forward to approval, and improve the landscape of treatment for arthritis and autoimmune diseases.
ANRF is a donor to ImmuneBoost Capital and a critical partner in realizing our mission. However, IBC operates independently, and is run by an experienced team of investors, scientific researchers, and medical and healthcare professionals.
ImmuneBoost Capital is registered as a non-profit with 501(c)(3) status. As a venture philanthropy fund, neither management nor donors to IBC will receive capital distributions. Profits from investments made by IBC will be reinvested back into advancing our mission.
Contact info@immuneboostcapital.org | www.immuneboostcapital.org | 888-624-0619
Sai Nandi, D.Phil.
Fund Principal
Immune Boost Capital
Emily Stormoen
CEO
ANRF
Jeff Greenberg, MD
Chair, IBC
Life Science Venture Thermo Fisher Scientific
Schalon Newton, DBA
Vice Chair, IBC
Leonard Dragone, MD
Treasurer, IBC
Johnson & Johnson Innovative Medicine
KT Moortgat, PhD
Secretary, IBC
Dalena Capital
Ayo Akandeff
Board Member, IBC
Retired Johnson & Johnson Innovative Medicine
DB Kartik
Board Member, IBC
JPA Health
Rich Narido
Board Member, IBC
Life Sciences
Piet van der Graaf, PharmD, PhD
Board Member, IBC
Certara
By contributing to Immune Boost Capital, you’re helping bridge the critical gap between early-stage research and life-changing therapies. Unlike traditional giving, your support here is multiplied—investments made through the Fund generate returns that are reinvested directly back into advancing new solutions. This means every dollar works harder, moving promising science into development more quickly and bringing innovative treatments closer to patients who need them most. With your partnership, we can accelerate discovery, amplify impact, and unlock the future of autoimmune and arthritis care.
